NanoViricides Inc. (NNVC): The takeaway here is that the IP may wel...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Monday, 03/11/2013 1:00:35 PM

Monday, March 11, 2013 1:00:35 PM

The takeaway here is that the IP may well cover the delivery of other forms of drugs such as bactericides.

Keep Last Read

Replies (2) Next 10 Prev Next

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM

InvestorsHub NewsWire

Only $200 per official company press release!